K
KBI Biopharma
KBI Biopharma | World Class CMO/CDMO Biologics Services
About KBI Biopharma
KBI Biopharma is a Contract Development and Manufacturing Organization (CDMO) that specializes in accelerating the development of innovative biological products. The company serves a diverse range of clients, including early-stage biotech firms, global pharmaceutical companies, and academic non-profit organizations. KBI Biopharma operates in the biopharmaceutical market, focusing on transforming scientific discoveries into life-changing medicines. The business model is centered around providing rapid cell line generation services using established mammalian and microbial recombinant protein expression systems, such as CHO K1, CHO S, CHO DG44, HEK293, and DXB11 E. coli. These services are designed to meet the timeline and budgetary objectives of preclinical programs. KBI Biopharma generates revenue through its comprehensive suite of development and manufacturing services, which include both standalone cell line development and fully integrated process development programs. The company aims to reduce risk and build value for its clients while expanding global access to essential medicines.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Employees
- 1,694
- Open positions
- 54
- Dealroom signal
- 39.0/100
- Industry
- Health
- Sub-industry
- Pharmaceutical, BioTechnology
- Sector
- Biotechnology, Drug Development, Biotech and Pharma, proteomics, DT and LS, science-based
- Business model
- Manufacturing
- Client focus
- B2C
- Investment activity
- 8 companies, latest Jan 2020
- Capital deployed
- $48M
- Preferred round
- SERIES A
News
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| LATE VCOther financing | Oct 2025 | $100M | $399M | Jsr | ↗ |
| FundingOther financing | Dec 2016 | $0 | — | Undisclosed | ↗ |
Growth signals
Latest recorded traffic for KBI Biopharma is 100K monthly website visits, up 29.9% over the last three months. KBI Biopharma's team grew 2.2% over the past year.
Open positions
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
AbSciVancouver, United StatesThe global leader in cutting-edge protein production technologies committed to reducing costs in the biopharmaceutical industry
$1.3Bvaluation
Comera Life SciencesWoburn, United StatesEnhancing therapeutic protein formulations for better patient experience and extended product lifecycle
$3Kvaluation
ReformbiologicsWoburn, United StatesTechnology platform transforming biotherapeutic formulations to extend product life cycles, enable alternative dosing, and improve manufacturing efficiency
→
EL
Elion LabsLouisville, United StatesElion Labs, a contract services organization
→
GlycoSeLectDublin, IrelandGlycoSeLect specializes in the development and production of glycoprotein separation technology using lectin chemistry
$2Mvaluation
AL
Alliance Protein LaboratoriesCalifornia City, United StatesContract research and consulting firm
→
Spyre Therapeutics | Aeglea BioTherapeuticsWaltham, United StatesDevelops engineered antibodies with extended half-lives to provide high-potency monotherapies and rational combinations for inflammatory bowel disease
$7.4Bvaluation
KBI Biopharma in the Durham ecosystem
The KBI Biopharma office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series B and later1 investor entered at this stage
Jsr
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about KBI Biopharma on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See KBI Biopharma’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.









